The Miller Laboratory focuses on the identification of cancer signaling pathways and the development of targeted therapies for breast and other cancers.
So happy that my #F31 has been officially awarded by the #NCI! Grateful for all of the support from my sponsoring team and friends who had to hear me fuss about grant writing for years😆
So happy that my #F31 has been officially awarded by the #NCI! Grateful for all of the support from my sponsoring team and friends who had to hear me fuss about grant writing for years😆
Looking forward to launching a new line of investigation into "Rational combination of endocrine and radiation therapies for ER+ breast cancer" supported by a new Prouty Pilot Grant to Todd Miller, Lesley Jarvis, and Rongxiao Zhang.
Congratulations to Steven Tau on his first manuscript from his PhD work!
Thanks to the entire team for their efforts to complete this pharmacology study.
Congratulations to our own Steven Tau for being selected to give a platform presentation at the 2022 Cancer Molecular Therapeutics Research Association Annual Meeting!
Congratulations to Dr. Shee et al. on acceptance of their manuscript in PLoS ONE.
Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
@PEMMatDartmouth
Congratulations to Drs. Fadul and Miller on publication of findings from their clinical trial in glioblastoma!
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
https://t.co/A07M5ehuKd
@PEMMatDartmouth
New publication!
A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
by Shee, Wells, Miller, et al. in Clinical Cancer Research.
https://t.co/vD7hBIcMk2
@PEMMatDartmouth
Another publication!
Statistical determination of synergy based on Bliss definition of drugs independence.
by Demidenko and Miller in PLoS ONE.
@PEMMatDartmouth